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Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease caused by degeneration of upper and lower motor
neurons. To date, glycosylation patterns of glycoproteins in fluids of ALS patients have not been described. Moreover, the
aberrant glycosylation related to the pathogenesis of other neurodegenerative diseases encouraged us to explore the
glycome of ALS patient sera. We found high levels of sialylated glycans and low levels of core fucosylated glycans in serum-
derived N-glycans of patients with ALS, compared to healthy volunteer sera. Based on these results, we analyzed the IgG Fc
N
297-glycans, as IgG are major serum glycoproteins affected by sialylation or core fucosylation and are found in the motor
cortex of ALS patients. The analyses revealed a distinct glycan, A2BG2, in IgG derived from ALS patient sera (ALS-IgG). This
glycan increases the affinity of IgG to CD16 on effector cells, consequently enhancing Antibody-Dependent Cellular
Cytotoxicity (ADCC). Therefore, we explore whether the Fc-N
297-glycans of IgG may be involved in ALS disease.
Immunostaining of brain and spinal cord tissues revealed over-expression of CD16 and co-localization of intact ALS-IgG with
CD16 and in brain with activated microglia of G93A-SOD1 mice. Intact ALS-IgG enhanced effector cell activation and ADCC
reaction in comparison to sugar-depleted or control IgG. ALS-IgG were localized in the synapse between brain microglia and
neurons of G93A-SOD1 mice, manifesting a promising in vivo ADCC reaction. Therefore, glycans of ALS-IgG may serve as
a biomarker for the disease and may be involved in neuronal damage.
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Introduction
Immunoglobulins, the major secretory products of the adaptive
immune system, include the glycoprotein IgG subclass, which
identifies and neutralizes foreign cells [1]. As adaptors, IgG
activate an immune response by simultaneously binding antigens
through their variable domains (F(ab)2) and through interaction of
their Fc domain with Fcc receptors (FccR) on immune cells. The
human FccR family consists of the activating receptor FccRIIIA
(CD16) that mediates antibody-dependent cellular cytotoxicity
(ADCC) [2]. The binding capacity of IgG to CD16 was found to
be lost after cleaving or preventing glycosylation at a single site on
asparagine 297 (N
297) in the IgG Fc domain [3]. The nature of the
glycans attached to N
297 affects the affinity of the CD16
interaction and thus governs antibody cytotoxicity [4]. It has
been suggested that IgG play a role in motor neuron degeneration
[5,6]. This was based on the finding of IgG deposits on the spinal
cord and brain of patients with amyotrophic lateral sclerosis (ALS)
and in animal models of inherited ALS. It was further found in
animal models that IgG from ALS patients could not be uptaken
by motor axon terminals after removal of the IgG Fc domain [7].
Consequently, it appears that FccRs are involved in IgG
deposition or in uptake by motor neurons.
ALS is a fatal neurodegenerative disease caused by degeneration
of the upper and lower motor neurons [8]. ALS patients and
animal models of inherited ALS, like mutant Cu/Zn superoxide
dismutase (mSOD1), display similar inflammatory responses at the
site of the motor neuron injury, enabling both the CNS resident
and systemic inflammatory cells to balance between neuroprotec-
tion and neurotoxicity [8–13]. Among others, microglia cells are
activated during these inflammatory responses, changing their cell
morphology and surface receptor expression, and producing
growth factors and cytokines, leading to neuron protection or
injury depending on the physiological conditions [14]. The
manners in which the signals switch between protective to
cytotoxic microglia are not yet fully understood. However, ALS
progression is attributed, in part, to cytotoxic microglia cells,
which secrete proinflammatory cytokines leading to neuron
damage. Cumulative data demonstrate that Toll-like receptors
or T-cells interacting with microglia are involved in inducing
cytotoxic microglia [15], but no direct evidence has been found
hitherto linking FccR to microglia activity in ALS. Notably, in
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evidence that the FccRs are linked to phagocytosis by activated
microglia [16].
We propose that over-expression of CD16 on activated
microglia or infiltrating immune cells can increase the incidence
of binding ALS-produced IgG through an Fc glycan, A2BG2, thus
inducing neuron loss. Here we tested this hypothesis by first
applying the N-glycome approach and then by demonstrating
over-expression of CD16 and co-localization of ALS-IgG with
CD16 in sections of brain and spinal cord tissues from 130- and
75-day old G93A-SOD1 mice. Additionally, we demonstrated in
vitro activities of intact ALS-IgG with this Fc glycan, including its
role in ADCC against neuroblastoma and neuroblastoma-spinal
cord motoneuron hybrid cell lines. Finally, we showed localization
Table 1. Statistic analyses comparing N-glycans derived from 19 ALS patient sera and from 24 healthy candidate sera.




(p Value) Fold Change
1 A2 0.578 0.230 0.605 21.13
2 Fc(6)A2 0.277 0.123 0.238 21.09
3 Fc(6)A1G1 0.434 0.317 0.432 21.09
4 Fc(6)A2G1 0.058 0.047 0.043 21.15
Fc(6)A2BG1
Fc(6)M4A1G1
5 A2G2 0.118 0.063 0.140 +1.83
M6A1
6 Fc(6)A2G2 0.008 0.020 0.003 21.32
Fc(6)A2BG2
Fc(6)M6A1




8 Fc(6)A2BG1S1 0.012 0.014 0.009 21.16
A2G2S1
Fc(6)A2G2S1






















Fold of change: (+) assigns that N-glycan amounts in ALS sera are higher relative to glycans from healthy candidate sera and (2) assigns the contrary.
doi:10.1371/journal.pone.0035772.t001
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microglia and the neuron of G93A-SOD1 brain tissue, thus
suggesting the occurrence of in vivo ADCC.
Materials and Methods
Ethics Statement
The study was performed in conformity with the Declaration of
Helsinki, and approved by the Ethics Committee of Ben-Gurion
University and of Tel-Aviv University. All subjects gave written
informed consent prior to participation.
Human subjects
Sera were collected from 19 ALS patients (11 males). The
average patient age at sampling was 60613 years (range 28–80)
and the average duration of the disease was 26613 months (range
9–54). Two patients had familial ALS. There was a relatively high
incidence of bulbar-onset patients in our sample (9–47%). The
average disability of the patients at the time of the examination, as
measured by the ALSFRS-R score was 3467 (range 17–44).
For control experiments, sera were collected from 24 healthy
subjects (13 males) with an average age of 48611 years. As non-
ALS disease controls, sera were taken from 22 patients (12 males)
with inflammatory bowel disease, with an average age of 44614
years. Ten patients had Crohn’s disease and the rest suffered from
ulcerative colitis. As an additional control for neurodegenerative
disease, sera were taken from 6 patients with multiple sclerosis with
an average age of 42617 years.
Blood collection and analysis
The collected blood samples were collected in 10 ml SST
Vacutainers (BD Biosciences, San Jose, CA) and allowed to clot at
4uC for 30 min. Coagulated blood was centrifuged at 3,000 rpm
for 10 minutes, and the serum portion was immediately divided
into 50 ml aliquots in low-binding vials and frozen for storage at
280uC until thawed for glycomic and immunologic analyses. The
aliquots were coded by the Sourasky hospital, where the sample
information was not available to the laboratory research assistants.
Two research assistants carried out the glycomic experiments. One
assistant used the individual and pooled samples, the other used
the individual samples, providing two independent experiments.
Glycan separation and normal phase HPLC analysis
In accordance with previous procedure [17], PNGase-F-
released glycans (Roche Diagnostics, Germany) from 50 mlo f
serum were fluorescently labeled with 2-aminobenzamide (2-AB),
by reductive amination. The glycans were subsequently separated
on a 4.66250 mm Glyco-Sep N column (Waters, Milford, MA)
using two Waters 510 pumps, a Waters 717 auto-injector, and
a FP-920 fluorescent detector (Jasco, Easton, MD). The solvents
used were buffer A (50 mM ammonium formate, pH 4.4) and
buffer B (acetonitrile). The glycans were eluted by a linear gradient
of buffer A, such that initial conditions were 20% buffer A at a flow
rate of 0.4 ml/min. The concentration of buffer A was changed
from 35–53% (the remainder was buffer B) over 132 min, and
then from 53–100% over the next 3 min, at a constant flow rate.
The column was washed with 100% buffer A for 5 min at a flow
rate of 1 ml/min before re-equilibration in the initial solvent
system. In order to determine the glycan structures, eluted glycans
from individual samples were collected manually according to
retention time, concentrated in a speed vacuum, and finally pooled
into ALS and control samples. Likewise, eluted glycans from 19
ALS patients and 24 healthy control samples were numbered
according to retention time and their amounts were calculated by
Empower software (Waters). Glycans were assigned glucose unit
(GU) values, and their structures were predicted by comparison to
a glycan database made available for use in this analysis.
Exoglycosidase digestions
Exoglycosidase digestion was used to define the structures of
glycans present in the pooled and the individual samples, in
conjunction with HPLC. A series of exoglycosidases supplied by
Prozyme (San Leandro, CA) was applied to the 2-AB-labeled N-
glycans to remove their terminal sugar residues. The digestions
were conducted using 50 mM sodium acetate buffer, pH 5.5, for
16 h at 37uC, at the following concentrations: 1 U/ml Arthobacter
ureafaciens sialidase (ABS); 1 U/ml bovine testis b-galactosidase
(BTG); 120 U/ml Streptococcus pneumonia b-hexoaminidase (SPH);
100 U/ml bovine kidney fucosidase (BKF); and 100 mU/ml jack
bean a-mannosidase.
IgG purification
Serum IgG from ALS, inflammatory bowel disease, and
multiple sclerosis patients, as well as from healthy controls were
purified using protein G sepharose beads according to the
manufacturer’s instructions (GE healthcare, Germany). Briefly, 1
Figure 1. The Fc-N
297-glycan of ALS-IgG contains a galactosy-
lated glycan with bisecting-GlcNAc and lacking a core fucose.
ANOVA t-test analysis of glycan amounts in individual or in pooled
serum samples of healthy controls and inflammatory bowel disease,
multiple sclerosis and ALS patients The glycan amounts and structures
were determined by NP-HPLC and MALDI-TOF MS methods (A), ANOVA
t-test analysis of A2BG2 with respect to gender (B) and age (C). Data
represent means 6 SD of measurements of 19 ALS, 24 healthy controls,
22 inflammatory bowel disease patients, and 6 multiple sclerosis
patients or 6 pools generated by mixing four individual serum samples
from every group (in multiple sclerosis two pools were generated by
mixing three individual serum samples). Statistical significance, ***
p,0.005, ** p,0.01 and *, p,0.05, versus the appropriate control.
doi:10.1371/journal.pone.0035772.g001
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buffer (20 mM sodium phosphate, pH 7.0) and applied onto
a protein G column. After 1 h of incubation at room temperature
under rotating conditions, the beads were washed, the IgG fraction
was eluted with 100 ml of elution buffer (0.1 M glycine-HCl,
pH 2.7), and the supernatants were collected into 1 M Tris-HCl,
pH 8.5, to neutralize the IgG solutions to pH 7.5. IgG concen-
tration was determined by Bradford assay (Bio-Rad, Hercules,
CA). IgG molecules were purified from individual serum samples
(total of 71 samples), or from pool samples; a typical pool sample
consisted of a balanced-serum mixture of four individuals.
Digestion of IgG Fc N-glycans
IgG molecules were reduced in Laemmli sample buffer (Bio-
Rad) and 50 mM DTT for 10 min at 70uC, followed by loading
on one dimensional SDS-PAGE gels (10%). The gels were run in
a MiniProtean3 device (Bio-Rad) for 75 min at 140–170 mV, at
a current lower than 350 mA [18]. The IgG molecules were
visualized with Coomassie blue stain and the relevant bands were
excised, cut into small pieces and dried using vacuum centrifuga-
tion. In accordance with previous procedure [17], three units of
PNGase F diluted in 27 ml of 20 mM NaHCO3, were added per
15 mm
3 of gel and incubated for 16 h at 37uC. N-glycans were
extracted from the gel pieces by collecting the supernatants of
sequential gel incubations with 36200 ml double distilled water
(DDW), 200 ml acetonitrile (ACN), 200 ml DDW and finally
200 ml ACN in a sonicating water bath for 30 min at room
temperature. The collected supernatants were concentrated to
a volume of 500 ml and then decontaminated using AG-50 (H
+
activated) ion-exchange resin. The glycans were dried for
fluorescent labeling and HPLC analysis.
N-glycan analysis by matrix-assisted laser desorption
ionization time-of-flight mass spectrometry (MALDI-TOF
MS)
The HPLC-eluted glycans were collected according to retention
time, concentrated in a speed vacuum and finally pooled into ALS
and control samples. The samples were diluted in 1 ml DDW,
desalted on a nafion membrane at room temperature for 30 min
and mixed with equal volumes of saturated 2,5-dihydroxy benzoic
acid (DHB) solution (Bruker Daltonics, Bremen, Gemany), 50%
ACN and 50% trifluoroacetic acid (TFA). The mixtures were
analyzed by MALDI-TOF MS (Bruker Daltonics). A peptide
calibration standard (Bruker Daltonics) was used to calibrate all
spectra.
Removing N
297 glycans from IgG
IgG N
297 glycans were removed by loading 50 ml of serum
pooled from ALS patients onto protein G sepharose beads for 1 h
at room temperature, with slow rotation. The beads were washed
with glycan digestion buffer containing 0.01 M NH4HCO3,
pH 8.5, followed by incubation with 0.5 U PNGase-F for 16 h
at 37uC, under rotation conditions. The supernatant containing
the digested glycans was removed and the N-glycan-free IgG
molecules (deglycosylated IgG or PNGase F-treated IgG) were
collected after elution and neutralization, as described above. The
digestion was confirmed by one dimensional SDS-PAGE gels
(10%) and immunoblot using Erithrina cristagalli lectin (ECL,
Vector, Burlingame, CA), as previously described [18].
Cell cultures
The human SHSy5y neuroblastoma (CRL2266, ATCC,
Manassas, VA), HeLa (CL-2, ATCC) and PANC1 (CRL1469,
ATCC) cell lines and the mouse neuroblastoma-spinal cord
motoneuron hybrid cell line (NSC 34, a generous gift from Prof.
D. Offen,) were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% (v/v) fetal calf serum (FCS), 100
Table 2. Statistic analyses comparing N
297-glycans digested from serum IgG of 19 ALS patients and of 24 healthy candidates.
Peak no. Assignment ANOVA (p-Value)
Mann-Whithney
(p-Value) Welch T-test (p-Value) Fold Change
1 A2 0.9 0.693 0.9 21.03
Fc(6)A1
2 Fc(6)A2 0.906 0.717 0.906 21.02
3 Fc(6)A2B 0.768 0.974 0.768 21.05
4 A2G1 0.288 0.293 0.289 21.19
5 Fc(6)A2G1 0.027 0.038 0.029 21.1
Fc(6)A2BG1
A2BG1
6 A2G2 0.797 0.717 0.797 +1.04
7 A2BG2 0.0027 0.004 0.0033 +2.1
8 Fc(6)A2G2 0.276 0.341 0.281 21.12
9 Fc(6)A2BG2 0.737 0.669 0.738 21.06
10 A2G2S1 0.254 0.178 0.259 +1.18
11 A2G2S2 0.473 0.622 0.474 +1.15
12 Fc(6)A2G2S1 0.14 0.450 0.152 +1.6
13 Fc(6)A2G2S2 0.202 0.237 0.215 +2.9
Fold of change: (+) assigns that N
297glycan amounts in ALS IgG are higher relative to N
297glycans from healthy control IgG and (2) assigns the contrary.
doi:10.1371/journal.pone.0035772.t002
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glutamine, in a humidified 5% CO2 atmosphere at 37uC.
The murine BW thymoma cell line, CD16-stable transfectants
of BW cells [19], and the THP1 cell line (TIB-202, ATCC) were
cultured in complete Roswell Park Memorial Institute medium
(RPMI-1640) supplemented with 10% (v/v) heat inactivated FCS,
100 units/ml penicillin, 0.1 mg/ml streptomycin, and 2 mM L-
glutamine in a humidified 5% CO2 atmosphere at 37uC, all from
Invitrogen (Carlsbad, CA).
Isolation of PBMCs and enriched peripheral NK cells
Human primary peripheral blood mononuclear cells (PBMCs)
were purified from whole blood of healthy donors using Ficoll-
Paque PLUS (GE Healthcare) according to the manufacturer’s
instructions. For isolation of a NK cell subset, PBMCs were
Figure 2. Expression and co-expression of CD16 with microglia of G93A-SOD1 brain and spinal cord tissues. Representative confocal
microscopic images of brain cortex and spinal cord slices taken from 130-day old G93A-SOD1 mice and age-matched littermates stained for CD16,
Iba1 (microglia), and counterstained with nuclear DAPI (A) The boxed area in A is a high magnification of CD16-positive microglia (small images in the
merged images, A, left); Spinal cord slices taken from 75-day old G93A-SOD1 mice and age-matched littermates stained similarly as described in A
(B); Expression of CD16 in brain and spinal cord tissues of mSOD1 in comparison to wild-type mice (in 8 mm brain slices) (C); Co-expression of CD16
with microglia in mSOD1 relative to wild-type mice (D). The quantity of CD16 was analyzed by measuring red intensity per defined area and the
quantity of CD16 co-expressed with Iba1 was analyzed by measuring % of red intensity on a defined green intensity area. The measurements were
performed on five fields from 3–4 sections per mouse. Error bars indicate means 6 SD. The P value analysis *** p,0.005, ** p,0.01 and * p,0.05,
versus non-SOD1 littermates represent a comparison with an ANOVA t-test.
doi:10.1371/journal.pone.0035772.g002
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e35772Figure 3. ALS-IgG co-localized with CD16 and microglia cells in brain and spinal-cord tissues of G93A-SOD1 mice. Representative
confocal microscopic images of brain cortex and spinal cord slices taken from 130-day old G93A-SOD1 mice and age-matched littermates stained for
CD16, hIgG, Iba1, NeuN (neurons) and counterstained with nuclear DAPI. Localization of ALS-IgG before and after PNGase-F treatment and of healthy
control-IgG in wild-type and mSOD1 brain tissues. The boxed area is a high magnification of CD16- and intact ALS-IgG-positive cell (A); Quantity of
Involvement of Fc-glycans in ALS Disease
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subsets were purified by negative selection using antibody-coated
magnetic bead separation (Invitrogen), following the manufac-
turer’s instructions. Cell subset purity was assessed by flow
cytometry, and determined to be 90%. The PBMCs or NK cells
used as effector cells were activated by culturing in 10% heat
inactivated FCS in RPMI-1640 containing 10 U/ml IL-2
(eBiosciences, San Diego, CA) overnight.
Flow cytometry
To determine IgG affinity to SHSy5y cells, 1610
5 cells were
harvested and blocked with FACS buffer (2% FCS and 0.05%
sodium azide in PBS, pH 7.5) (Biolegend, San Diego, CA).
Subsequently, the cells were incubated with pools of serum
samples or protein G-enriched IgG of ALS, inflammatory bowel
disease, multiple sclerosis patients or healthy controls at a dilution
of 1:10. Goat anti-human IgG allophycocyanin-conjugated F(ab9)2
(Jackson Immuno-Research, West Grove, PA) was used as a second
step reagent. Propidium iodide (PI) was used to stain dead cells.
For blocking CD16 on BPMCs, 1610
5 cells were incubated in
FACS buffer and purified anti-human CD16 antibodies (Biole-
gend). Subsequently, the cells were washed and incubated with
pools of serum samples of ALS patients. Goat anti-human IgG
conjugated with allophycocyanin (Jackson Immuno-Research) was
used as a second step reagent. Flow cytometry was performed
using a FACS Calibur flow cytometer (BD Biosciences), and
fluorescence data were acquired using logarithmic amplification.
Data files were acquired and analyzed using BD CellQuest 3.3
software.
Measurement of secreted cytokines
U-shape 96 well plates were incubated with serum, protein-G-
enriched IgG or serum-depleted IgG samples for 3 h in
a humidified 5% CO2 atmosphere at 37uC. After IgG absorption,
the plates were intensively washed and incubated with 1610
5
healthy donor-enriched NK cells or CD16-transfected and control
BW cells for 18 h in a humidified 5% CO2 atmosphere at 37uC.
The media were collected and levels of secreted human IFNc and
mouse interleukin IL-2 were assessed using a commercial ELISA
kit (Biolegend), according to the manufacturer’s instructions and as
described [19].
ADCC assay
Antibody-dependent cytolytic activity was evaluated in co-
cultures of neuroblastoma and NSC34 cells with serum or purified
IgG from the different samples and PBMCs in a 4 h CFSE/7-
AAD flow cytometry assay, as previously described [20].
Neuroblastoma and NSC34 cells, serving as target cells, were
pre-incubated with diluted sera (1:10) or with purified ALS-IgG
before and after removing N
297 glycans, for 1 h on ice. The cells
were washed in RPMI medium and plated at a density of 5610
4
cells per well of a 96-well plate. The isolated PBMCs were pre-
labeled with CFSE (Invitrogen) and co-cultured with the complex
IgG-target cells at effector/target (E/T) cell ratios of 10:1, in a final
volume of 200 ml RPMI medium at 37uC for 4 h in a humidified
CO2 incubator. To measure spontaneous lysis, target cell cultures
were used. For cytolytic activity independent of IgG, target cells
were co-cultured with PBMCs. For measuring lysis of target cells
by IgG, target cells were incubated with IgG or serum samples. To
confirm that the ADCC response occurred via NK cells, the
PBMCs were pre-treated with anti-CD16 antibodies (BD Bios-
ciences) for 30 min on ice and then co-cultured with target cells
before coupling with the IgG. Killing assays were performed in
quadruplicates. Acquisition was performed immediately after-
wards on a FACScan flow cytometer equipped with a single
488 nm Argon laser. CFSE fluorescence and 7-AAD emission
were detected in the FL-1 and FL-3 channels, respectively.
Analysis was performed with FlowJo software (Three Star,
Ashland, OR).
G93A-SOD1 mice and frozen sections
Frozen sections of brain and spinal cord tissues of G93A-SOD1
transgenic and wild-type mice were kindly donated by Prof. D.
Offen from Rabin Medical Center-Beilinson Campus, The
Sackler School of Medicine at Tel-Aviv University and from Prof.
M. Schwartz from The Department of Neurobiology at The
Weizmann Institute of Science. The G93A-SOD1 transgenic mice
were purchased from the Jackson Laboratory and were bred and
maintained in the animal breeding center of the Tel-Aviv
University (Approval ID 034-b328-4) and of the Weizmann
Institute (IACUC; permission number 03680806-1). All experi-
ments and procedures were approved by the Animal Care and Use
Committee of Tel-Aviv University and of the Weizmann Institute.
For this experiment, G93A-SOD1 transgenic mice, 130 day old
(the end-stage of the disease) and 75 day old [21] and wild-type
age-matched littermates were deeply anesthetized, decapitated,
and perfused with isotonic saline followed by 4% paraformalde-
hyde via cardiac puncture. Brain and spinal cord organs were
immediately equilibrated in a 30% sucrose solution for 24 h,
embedded in a frozen tissue matrix (Tissue-Tek OCT, Torrance,
CA), cryo sectioned and stored at 280uC until section staining.
Immunohistochemistry
Tick slides of 8 mm were blocked in PBS containing 1% BSA for
1 h and stained with mouse anti-neuronal nuclear protein (NeuN;
1:25, GeneTex, Irvine, CA), mouse anti-CD16 (ASH 1975; 1:50,
Santa-Cruz Biotechnologies, Santa Cruz, CA), rabbit anti- ionized
calcium binding adaptor molecule 1 (Iba-1; 1:1000, Chemicon,
Billerica, MA) antibodies, protein-G-purified ALS-IgG treated or
untreated with PNGase F, and healthy volunteer IgG, at
concentrations of 16 mg/ml. Anti-mouse CY5-, anti-rabbit CY3-
, anti-human FITC-tagged or anti-mouse dyelight 549 secondary
antibodies with low cross reactivity to other species (Jackson
Immuno-Research), were used for cell visualization. For pre-
serving fluorescence and for nuclei detection, a drop of VECTA-
SHIELD mounting medium with DAPI was added (Vector). The
sections were examined under a Zeiss Laser Scanning Confocal
Microscope, using a 660 magnification lens. The percentage of
co-expression/localization was calculated by measuring the ratio
between two crossed intensities in a defined area using an
Olympus Fluoview FV1000 version 2b.
ALS-IgG accumulation before and after PNGase-F treatment and of IgG from healthy control in mSOD1 brain slices (B); Quantity of ALS-IgG before
and after PNGase-F treatment and of IgG from healthy control co-localized with CD16 in wild-type and mSOD1 brain tissues (C); Co-localization of
intact ALS-IgG with microglia was detected in mSOD1 brain tissue (D), and co-localization of intact ALS-IgG with NeuN in mSOD1 brain and spinal
cord tissues (E). The measurements were performed on five fields from 3–4 sections per mouse. Error bars indicate means 6 SD. Asterisks denote the
significance of differences relative to deglycosylated ALS-IgG or control-IgG in mSOD1 sections or ALS-IgG in non-SOD1 littermates, *** p,0.005
represents a comparison using ANOVA t-test.
doi:10.1371/journal.pone.0035772.g003
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For measuring the amounts of total N-glycans in serum and for
determining the IgG glycan structures and their amounts,
individual serum samples of each group were used. The data
shown correspond to pooled or single representative experiments,
as indicated, and are expressed as mean values 6 SEM.
Significant differences in results were determined using three t-
tests; the Mann-Whitney test, the Welch t-test, and ANOVA, with
p,0.05 in the triplet tests being considered as significant. The p
value observed for N-glycans was calculated before multiple
testing. The p values after multiple testing differed insignificantly
compared to the values before. All statistical analyses were
performed at the Bioinformatics Core Facility at Ben-Gurion
University using PartekH Genomics Suite
TM software.
The in vitro experiments were repeated at least 3 times with
similar patterns of responses. The data shown correspond to
pooled or single representative experiments, as indicated, and are
expressed as mean values 6 SD. Significant differences in results
were determined using the two-tailed ANOVA t-test, with p,0.05
being considered as significant.
Results
Sequencing N-glycans derived from intact serum
glycoproteins
Based on the presence of various blood substances in the
cerebrospinal fluid [22], we hypothesized that the serum substance
repertoire of ALS patients might contain uncommon glycoforms.
Accordingly, we sequenced total N-glycans derived from serum
samples of ALS patients and healthy volunteers. Whole serum N-
glycans from 19 patients were fractionated by quantitative NP-
HPLC, according to glucose units (GU). The thirteen fractions
observed were numbered (Fig. S1) and each was pooled and
subsequently digested by exoglycosidases, with structural assign-
ments being made using database-matching, combined with
MALDI-TOF MS. The results from the pooled fractions were
compared to those of control samples pooled from fractionated N-
glycans of 24 healthy volunteer sera. The results revealed a similar
number of fractions and glycan structures in both patient and
healthy serum samples. Most of the fractions contained 3–5 glycan
structures, namely bi- or tri-antennary high mannose and complex
type structures (Table S1). The complex structures were
composed of neutral and multi-sialylated glycans. Some of these
were core fucosylated, while others bore bisecting N-acetyl
glucosamine (GlcNAc) or sialyl-Le
x epitopes. Despite the fact that
many structures were found to be capped by sialic acid residues,
separation by weak ion-exchange HPLC according to charge
failed to provide full sequencing information due to partial glycan
separation (data not shown). Thus, the glycans partially sequenced
by NP-HPLC separation were next subjected to sample fraction-
ation.
In addition to the full sequencing of serum glycans, N-glycan
amounts from individual samples were calculated by dividing areas
under specific peaks to total peak area measured in each HPLC
spectrum. Following t-test analyses of the individual samples, 4
fractions met statistical criteria (P,0.05) and were selected as
candidate disease glycans (Table 1, Table S2). Two of the
fractions, peaks 10 and 13, contained abundant bi- and tri-
antennary glycans that included up to two sialic acid residues or
sialyl-Le
x epitopes. These structures were significantly up-regulat-
ed in ALS samples. The two other fractions, peaks 6 and 8, were
rich in core fucosylation and galactosylation and were plentiful in
healthy samples. The unique glycans detected upon individual
sample analysis were correlated with glycan alterations found in
the pooled samples. Thus, this pilot study indicates that glycans are
potential candidate markers of ALS. However, full serum glycome
analysis may not be successful in revealing differences in the
glycans of specific glycoproteins which might play a central role in
disease progression.
Sequencing the N
297 glycans of enriched IgG
The involvement of the IgG Fc domain in IgG uptake was
suggested in an ALS animal model [10]. Accordingly, IgG
molecules were purified from individual serum samples of 19
ALS, 22 inflammatory bowel disease, and 6 multiple sclerosis
patients, and from 24 healthy controls. N-glycans were released
from a total of 71 individual samples and separately analyzed by
NP-HPLC and MALDI-TOF MS. Results showed similar bi-
antennary complex structures (Fig. S2, Table S2, Table S3). T-
test analyses of glycan amounts in ALS and healthy subjects
revealed two structures in amounts that met our statistical criteria
as being unique N
297 glycans (Table 2). Similar Fc glycans
purified from healthy control IgG were observed, as compared to
ALS-IgG, except for one significant difference, namely, a galacto-
sylated structure with a bisecting GlcNAc lacking the core fucose
(A2BG2, peak no 7) was doubled in ALS-IgG. As well, the A2BG2
structure was significantly (P,0.015) up-regulated in ALS-purified
IgG, as opposed to in purified IgG from inflammatory bowel
disease or multiple sclerosis patients (Fig. 1A). Moreover, Fig. 1A
illustrates the amounts of A2BG2 structure in pools of healthy
controls, ALS, inflammatory bowel disease, and multiple sclerosis
patients. As can be seen, when pooling the individual samples from
each examined group and analyzing by NP-HPLC, similar
amounts of A2BG2 were observed as compared to individual
samples. To diminish differences of glycan structural alterations
with respect to other clinical parameters such as, sex and age, we
regrouped the serum sample by gender or age and performed
ANOVA t-test analysis. Fig. 1B and 1C show that A2BG2
amount does not change with respect to gender or age,
respectively. Hence for the next experiments, designed to elucidate
A2BG2 role in determining IgG activity, we used pooled samples.
However, as indicated in Table 2, double and triplicate glycan
amounts represented in peaks 12 and 13 respectively, were further
observed in patient samples, but found to be insignificant as
compared to healthy samples. Accordingly, patient and healthy
samples with similar glycan amounts represented in peaks 12 and
13 were selected to assemble the pools.
Abundant expression of CD16 and its co-expression with
microglia of G93A-SOD1 brain tissue
The indicated Fc glycan A2BG2 is known to increase IgG
coupling with CD16 on effector cells, thereby enhancing ADCC.
Therefore, in order to illustrate the expression of CD16, brain and
spinal cord tissues of 130-day and 75-day old G93A-SOD1 mice
and wild-type littermates were sectioned. Staining with anti-CD16
antibodies showed that CD16 was abundantly expressed by brain
and spinal cord tissues of 130- and 75-day old mSOD1 mice in
comparison to wild-type mice (Fig. 2A–B). However, CD16
expression in the brain tissue was enhanced in comparison to the
spinal cord tissue. Presumably, the level of CD16 depends on the
number and type of cells expressing this receptor. Therefore, we
next examined CD16 co-localization to microglia by staining with
CD16 and microglial markers. Co-expression of CD16 with
microglia cells was detected in the brain tissue sections (Fig. 2A).
Microglia in wild-type brain tissue expressed low levels of CD16
(yellow spots) and changed their morphology from ramified to
amoeboid in mSOD1 mice, whereas CD16 was expressed at the
branches and around the cellular body (the small images of wild-
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contrast, in spinal cord tissues of 130- and 75-day old mSOD1
mice, the CD16 receptor was poorly co-expressed with microglia.
The quantitative analysis summarizes the data shown in figure 2A–
B and shows that CD16 was significantly over-expressed in
mSOD1 brain and spinal cord tissues in comparison to the wild-
type counterparts (Fig. 2C). Specifically, CD16 was abundantly
co-expressed with microglia in brain tissue of mSOD1 mice in
comparison to that observed in wild-type brain tissue or in spinal
cord tissues of mSOD1 mice (Fig. 2D).
ALS-IgG co-localized with CD16 and microglia
To investigate whether the elevated amounts of A2BG2 glycan
enhance co-localization of ALS-IgG with CD16 and with
microglia, pools of IgG purified from healthy candidates or from
ALS patients, with and without the Fc N-glycans were used on
brain and spinal cord tissue sections of mSOD1 mice and wild-
type littermates. Intact ALS-IgG, with the Fc glycans, were
significantly found in 130-day old mSOD1 brain and spinal cord
tissues as opposed to lower localization of PNGase-F-treated ALS-
IgG and of IgG of healthy candidates in mSOD1-matched tissues
(Fig. 3A, B). Furthermore, localization of ALS-IgG in the wild-
type brain and spinal cord tissues was lower than observed in
mSOD1 tissues (Figure 3A, B). Similar results were observed in
spinal cord tissue sections of 75-day old mSOD1 mice (Fig. S3A).
However, at the early stage of the disease (75 days), less ALS-IgGs
were detected on the sections in comparison to the final stage of
the disease (130 days).
Co-localization of ALS-IgG with CD16 in mSOD1 brain tissue
was largely detected on cell surface and branches, apparently of
microglia cells (Fig. 3A, C). Double staining verified that intact
ALS-IgG co-localized with mSOD1 microglia cells, where the IgG
positioned around the microglia cellular body (Fig. 3D) and
branches. Approximately, 65% of the total number of microglia
per field bound ALS-IgG. However, ALS-IgG were also detected
near the nuclei of other cells, especially in spinal cord tissues.
These results are in contrast to those observed when using
PNGase-F-treated ALS-IgG or IgG of healthy samples, on
mSOD1-matched sections (Fig. 3A, C).
Staining of neurons and ALS-IgG indicated that ALS-IgG were
co-localized with neurons in brain and spinal cord tissues of 130-
day old mSOD1 mice (Fig. 3E) and in spinal cord tissues of 75-
day old mSOD1 mice (Fig. S3B).
Taken together, our results related to the increase in amount of
IgG-A2BG2 glycoform in ALS sera, the CD16 over-expression in
tissue sections of G93A-SOD1 mouse brains and spinal cords, and
the co-localization of ALS-IgG with CD16 and brain microglia,
suggest that N-glycans of ALS-IgG may be involved in ADCC
reactions. Therefore, our next step was to illustrate the ALS-IgG
involvement in ADCC.
Binding of serum IgG to a human neuroblastoma and
mouse NSC34 cell lines and to lymphocyte CD16
Initially, we verified that neurons can serve as antigenic targets
for ALS-derived IgG [23–25], and that they poorly bind IgG from
healthy controls or from inflammatory bowel disease or multiple
sclerosis patient samples. As such, neuroblastoma cells blocked by
anti-CD16/CD32 antibodies were incubated with pools of serum
samples or with purified IgG and then assessed by FACS. The
blocking step was performed only in the experiments of binding
IgG to the target cells in order to reduce unspecific binding. The
binding of either purified or unpurified ALS-IgG to the surface of
the neuroblastoma cells was elevated, in comparison to such
binding by pools of IgG from healthy control (Fig. 4A, B), or by
IgG pools from inflammatory bowel disease (Fig. 4A) or from
multiple sclerosis patients (Fig. 4A). Comparing the specificity of
ALS-IgG binding by neuroblastoma, HeLa and PANC1 cells
revealed significant differences between neuronal and non-
neuronal cells (Fig. 4C). To confirm the latter result but with
the appropriate target cell, we repeated the binding experiments
using neuroblastoma-spinal cord motoneuron hybrid cell line,
NSC34 exposed to different serum concentration. As opposed to
neuroblastoma, NSC34 cells bound ALS-IgG in a similar manner
as they bound IgGs from healthy controls (Fig. 4D). This is
particularly important when demonstrating the cytotoxic effects of
IgGs via their coupling to CD16 in the ADCC reaction.
Hence, we next investigated whether the elevated amounts of
A2BG2 glycan in the Fc domain found in ALS-IgG increase the
affinity of these antibodies to CD16 [2,3] by measuring cytokine
production and the percentage of IgG binding to CD16. Pools of
serum samples from healthy controls, ALS, from patients with
inflammatory bowel disease and from multiple sclerosis patients,
containing similar concentrations of IgG were incubated with
purified human peripheral NK cells for 18 h. In addition, pools of
serum samples from healthy controls and ALS or ALS-IgG and
ALS IgG-depleted sera were incubated with BW-CD16-trans-
fected or normal BW cells [26], for 18 h. NK cells containing
CD16 and BW-CD16 transfectants produced IFNc and IL-2,
respectively, in response to Fc ligand coupling. ELISA results
demonstrated that NK cells were activated by ALS patient sera to
produce augmented amounts of IFNc, while inflammatory bowel
disease patient, multiple sclerosis patient or healthy control sera
induced lower IFNc production (Fig. 4E). Moreover, more than
double the amount of IL-2 was produced by BW-CD16
transfectants in response to ALS patient sera, as compared to
healthy control sera, while normal BW cells incubated with any
sera did not produce IL-2 (Fig. 4F). In response to purified IgG,
BW-CD16 transfectants produced more than 8-fold amount of IL-
2, whereas negligible amounts of IL-2 were produced in response
to ALS IgG-depleted sera (Fig. 4G). By FACS and several
dilutions, examination of the specific coupling to CD16 of PNGase
Figure 4. Coupling of IgG to target neuroblastoma and NSC34 cells and to CD16 on effector cells. FACS histograms presenting a shift in
binding of serum pools of ALS patients to human neuroblastoma cells in comparison to binding of healthy control (CON), inflammatory bowel
disease and multiple sclerosis serum pools to neuroblastoma cells (A); FACS histogram presenting shift in binding of purified IgG from serum pools of
ALS patients to neuroblastoma cells relative to binding of purified IgG from healthy control (CON) (B); Dose-dependent coupling of purified ALS-IgG
to human PANC1, HeLa, and neuroblastoma cells performed as described in A(C); Mean fluorescent intensity (MFI) calculated relative to control
sample containing cells and serum that was free of IgG. Dose-dependent coupling of ALS-IgG to mouse NSC34 cells was performed as described
above (D); Secretion of IFNc by enriched human peripheral NK cells in response to interactions with pools of ALS, inflammatory bowel disease
patients, patients of multiple sclerosis, and healthy control (CON) sera (E); Secretion of IL-2 by BW-CD16 transfectants or BW cells in response to
interactions with pools of ALS and healthy control sera (F), and in response to interactions with ALS-IgG and ALS IgG-depleted sera (G). Comparing
the specificity of dose-dependent coupling of PNGase F-treated or untreated IgG of ALS patients and of the IgG of healthy volunteers, to CD16 (H).
Data represent the mean 6 SD of triplicate measurements from independent duplicate experiments. Pools of healthy and patient samples contained
a mixture of four individual serum samples with similar glycan amounts represented in peaks 12 and 13. Statistical significance, *** p,0.005, **
p,0.01 and * p,0.05, versus the appropriate controls in each panel.
doi:10.1371/journal.pone.0035772.g004
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revealed significant differences between the IgG containing the
A2BG2 glycan to those lacking this glycan (Fig. 4H).
Loss of human neuroblastoma and mouse NSC34 cells
through the ADCC pathway
To illustrate the involvement of ALS-derived IgG in mediating
ADCC, cytotoxic assays were performed using human neuroblas-
toma or mouse NSC34 as target cells, PBMCs as effector cells and
pools from healthy controls, ALS, inflammatory bowel disease,
and multiple sclerosis patients as IgG sources. A lysis rate of 25%
was mediated by IgG from ALS patient sera (Fig. 5A), while
healthy control, inflammatory bowel disease patient and multiple
sclerosis patient sera mediated cytotoxicity of less than 10%
(Fig. 5A). A lysis rate of 7% was measured in samples of
neuroblastoma cells co-cultured with PBMCs and values of less
than 5% when neuroblastoma cells were incubated with IgG
samples to control for spontaneous cell lysis.
To illustrate the involvement of CD16 in the ADCC reaction
mediated by ALS-IgG, PBMCs were blocked with anti-CD16
antibodies and IgG were purified from pool samples. FACS results
show a significant decrease in coupling of ALS-IgG to PBMCs, as
detected by secondary antibodies (Fig. 5B left panel). Using the
CD16-blocked PBMCs in an ADCC reaction against neuroblas-
toma cells led to a 40% reduction in the cytotoxic response against
the target cells, in comparison to cell lysis with unblocked PBMCs
(Fig. 5C). To illustrate the effect of the A2BG2 glycoform on
neuroblastoma lysis, N-glycans were removed from ALS-IgG by
PNGase F treatment and the heavy chain was assessed by SDS-
PAGE and Western blot using ECL lectin conjugated to FITC. N-
glycans with galactose residues have high affinity to the ECL lectin
[27]. As can be seen, the heavy chain of ALS-IgG before PNGase
F treatment migrated with an average apparent molecular weight
of 50 kDa (lane 1) and was well labeled in the Western blot
protocol (lane 3) (Fig. 5B right). After PNGase F treatment,
however, the heavy chain band was shifted to an apparent
molecular weight lower than 50 kDa (lane 2), with the fluorescent
intensity associated with the immunoblot being quenched (lane 4)
(Fig. 5B right). When using ALS-IgG after PNGase F treatment
in an ADCC response against neuroblastoma cells, a two-fold
decrease in lysis was noted compared to using ALS-IgG bearing
N-glycans (Fig. 5C). In comparable experiments, killing of NSC34
target cells by PBMCs was conducted using intact ALS-IgG, ALS-
IgG treated with PNGase F and IgG from healthy control samples.
A similar killing pattern of NSC34 cells as measured for
neuroblastoma cells was mediated by intact ALS-IgG, the treated
IgG and those from healthy controls (Fig. 5D). Furthermore,
opsonizing of ALS-IgG by CD64 and CD32, which either leads to
target cell lysis was reversed by using THP1 cells expressing CD32
and CD64 but not CD16 [28], as an alternative to NK cells in the
cytotoxic assay (Fig. 5E). These observations indicate that CD16
on NK cells and the A2BG2 in ALS-IgG are involved in
neuroblastoma and NSC 34 cell loss.
Finally, to demonstrate the feasibility of in vivo ADCC, we
studied the localization of intact IgG derived from ALS patients
with both neuron and microglia of mSOD1 brain tissue, by triple
staining. Several ALS-IgG molecules were found to be located in
the immune synapse between microglia and the neuron, suggest-
ing the occurrence of ADCC (Fig. 5F). In contrast, such
localization was rarely observed in matched-sections when
PNGase-F-treated ALS-IgG were used (data not shown). Accord-
ingly, the Fc glycans are involved in IgG deposition in the brain of
an ALS animal model and plausibly take part in in vivo ADCC.
Discussion
Previous studies have shown that the glycan chain synthesis
machinery is highly sensitive to the biochemical environment and
can change during the course of a disease [29]. In neurodegen-
erative disorders such as Alzheimer’s and Creutzfeldt-Jakob
diseases, it was found that the glycosylation pattern of several
glycoproteins, such as reelin, or acetylcholinesterase, is associated
with disease pathogenesis [30,31]. Thus, the altered expression of
glycoproteins in the sera or cerebrospinal fluid of patients with
ALS [32,33] encouraged us to utilize a glycomics approach in the
hope of finding ALS-unique glycans in patient sera.
The present pilot study analyzes the N-glycome of both
individual and pooled sera, reflecting changes in N-glycan
quantities rather than in unique structures. We observed that
sialylated glycans are significantly increased in ALS patient sera
while fucosylated glycans are significantly decreased, as compared
to healthy control sera. Our results are in accordance with
previous studies showing increased glycan sialylation in breast and
ovarian cancer patient sera [34,35]. The results are, however,
opposed to studies that showed over-expression of fucosylated
glycans in sera of hepatocellular carcinoma and pancreatic cancer
patients [36,37]. Although similar glycan aberrations can be
observed in totally different types of diseases, the alterations
detected in ALS patient sera represent the first step in finding
candidate disease biomarkers. Identifying such markers depends
on a correlation with disease severity as measured by alternative
assays, which would be necessary to improve specificity and
sensitivity. Such identification also depends on a large scale study.
Whereas serum N-glycans can be considered as source biomarkers
for disease diagnosis and prognosis, profiling the glycans of specific
glycoproteins under disease conditions might also reveal the
involvement of glycans or glycoproteins in disease pathogenesis.
Based on the results of the N-glycome analysis reported, we
analyzed IgG-Fc glycans from patient or healthy sera, using
a second and more specific strategy [38]. As IgG are the most
abundant glycoproteins in serum, they were predicted to contain
Figure 5. Killing human neuroblastoma or mouse NSC34 cells through the ADCC pathway. ADCC was performed using human
neuroblastoma as target cells, PBMCs as effector cells, and pools of serum samples of ALS, healthy control, inflammatory bowel disease patients, and
multiple sclerosis patients as IgG sources. The controls contain: neuroblastoma cells incubated with IgG pools from the different serum sources and
co-cultures of neuroblastoma cells and PBMCs (A). FACS results from PBMCs pre-treated with anti-CD16 antibodies (B, left) and the heavy chain of
ALS-IgG before and after PNGase-F treatment in SDS-PAGE and Western blot using ECL lectin (B, right); ADCC mediated by CD16-blocked effector
cells or by ALS-IgG after PNGase-F treatment, as compared to the ADCC against neuroblastoma mediated by unblocked effector cells and untreated
ALS-IgG (C); Killing of NSC34 cells by ADCC as described above was mediated by intact (untreated) ALS-IgG, PNGase-F treated ALS-IgG and by IgG
from healthy controls (D). Neuroblastoma lysis by CD32- and CD64-positive THP1 cells was mediated by ALS-IgG, IgG of healthy controls, and in
serum free of IgG (E). Spontaneous lysis was measured in neuroblastoma or NSC34 cultures. Triple staining of NeuN, Iba1, and ALS-IgG by anti-human
IgGs conjugated to FITC demonstrates the localization of intact ALS-IgG in immune synapse (arrow) amongst microglia and neurons (F). Data
represent the mean 6 SD of triplicate measurements from triplicate independent experiments. Pools of healthy and patient samples contained
a mixture of four individual serum samples with similar glycan amounts represented in peaks 12 and 13. Statistical significance, ** p,0.01, * p,0.05
and NS (Not significant) is represented versus the appropriate controls in each panel.
doi:10.1371/journal.pone.0035772.g005
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serum N-glycome of ALS patients versus healthy volunteers. Also,
changes in fucosylation and sialylation in the Fc domain of IgG
were previously associated with ADCC and the inflammation
process, respectively [39–41]. Moreover, IgG molecules which
contain variable domains against neurons [24,25] were detected in
spinal cord motor neurons and in pyramidal cells within the motor
cortex of ALS patients. It was also found that the IgG-Fc domain is
necessary to the IgG uptake by motor axon terminals [7].
Therefore, it was suggested that IgG-Fc plays a role in the
pathogenesis of ALS and that ALS might be an autoimmune
disease [23,42]. Indeed, changes in IgG-Fc glycans have been
associated with autoimmunity [3]. Thus, two autoimmune diseases
were utilized here as comparable IgG sources, one a neurodegen-
erative disease, multiple sclerosis, and the other an inflammatory
bowel disease of the gastric system. We demonstrated the
expression of A2BG2 in the Fc domain of ALS-derived IgG. This
glycan was not detected in healthy control-derived IgG and
detected to low extent in IgG derived from patients with
inflammatory bowel disease or multiple sclerosis. In these diseases
as compared to healthy conditions, the inflammation determines
the expression of glycosyltransferases in B cells, thus the changes in
the Fc glycans. In contrast, a similar structure containing core
fucose was largely found in healthy control-derived IgG. This is
consistent with previous works showing high core fucosylation in
normal human IgG [43,44]. Therefore, A2BG2, which reflects, in
part, the reduced fucosylation observed in the serum N-glycome of
ALS patients, is an appropriate candidate for further exploration
of potential biomarkers for ALS diagnosis. Notably, a comparison
between the different IgG glycan sources indicated that a signif-
icant number of glyco-variants associated with autoimmunity [45]
were not found in ALS-IgG (data not shown).
Previously, it was shown that enhanced ADCC against cancer
cells could be achieved by engineered bisecting GlcNAc IgG
glycoforms [46,47], while weak ADCC was observed by IgG
glycoforms rich in core fucosylation [41]. The Fc glycans
determine the affinity to the activating receptor, FccRIII
(CD16). For example, core fucosylation of the N
297-Fc glycans
decreases the affinity to CD16 by 50-fold [41]. Therefore, we
hypothesized that considerable amounts of A2BG2 in ALS-IgG
would advance a higher ADCC. We pooled samples of ALS-IgG
or control IgG with similar glycan amounts, excluding the A2BG2,
and indeed showed that ALS-derived IgG better mediates ADCC
against neuroblastoma and hybrid of neuroblastoma-spinal cord
motoneuron cells by human peripheral NK cells, and that the lysis
was not a consequence of phagocytosis. Also, IgG coupling from
the healthy, the inflammatory bowel disease and the multiple
sclerosis patients led to a lower degree of neuroblastoma lysis,
indicating that cytotoxicity is specifically associated with the ALS
patient IgG. Pre-treatment of PBMCs with anti-CD16 antibodies
remarkably reduced the ADCC reaction mediated by ALS-IgG,
while an 18 h incubation of ALS-IgG with CD16-transfected BW
cells or peripheral NK cells induced IL-2 or IFNc, respectively.
Furthermore, removing N-glycans from the Fc of ALS-IgG by
specific cleavage also reduced the ADCC reaction. Our results are
in accordance with previous in vitro studies, providing evidence for
ALS-IgG but not for control IgG mediating of neuron loss [25,48].
These studies, however, showed the effects of IgG on neuron
apoptotic death by incubating the cells with only IgG in long-term
cultures. We suggest a pathway for neuron loss through ADCC
and show by in vitro study a plausible contribution of the IgG
A2BG2 glycan to this pathway.
Staining brain tissue sections derived from 130-day old G93A-
SOD1 mice by ALS-IgG or healthy control IgG, and staining for
CD16 on microglia and neurons supported our hypothesis for
neuron loss through ADCC that can be mediated by IgG with the
A2BG2 glycan. CD16 was more abundantly expressed in mSOD1
brain than in non-SOD1 littermates and co-expressed with
microglia, revealing the capability of this receptor to bind IgG
with A2BG2 glycan at a high frequency. Indeed, ALS-IgG
molecules with the Fc-glycan had a higher incidence of binding to
CD16 than those without the glycans or those from healthy
samples, and they localized amongst microglia and neurons. These
findings are in line with previous reports showing the Fc-domain
contribution to ALS-IgG uptake by motor axon terminals and the
Fcc receptor role in reducing ALS-IgG uptake, and attenuating
accumulation of intracellular calcium and acetylcholine release by
neurons [7]. Staining of spinal cord tissues supported most of the
findings revealed in brain tissue; excluding the co-localization of
CD16 with microglia cells. It is plausible that in the spinal cord
other CD16 bearing populations of infiltrate immune cells [14–15]
take part in the ADCC. Nevertheless, CD16 affects the IgG
position in the brain and spinal cord more than does the neuron
antigenic domain. This was further documented in the spinal cord
of 75-day old G93A-SOD1 mice, which are at the earlier stage of
the disease. The lower levels of ALS-IgG that were detected on
spinal cord tissue sections of 75-day in comparison to 130-day old
mSOD1 mice, can point to the role of IgG glycans in the
pathogenesis of ALS, as at the earlier stage of the disease the
pathological features are not solely a consequence of neurodegen-
eration as in the final stage of the disease.
The antigenic domains found in auto-antibodies of ALS patients
include Fas, neurofilaments, voltage-gated Ca
2+ channels, GM1
gangliosides [48–50] and the gangliosides, GD-2 and GD-3 [51].
It can be assumed that the frequent presence of an IgG fraction
containing a neuron-antigenic domain and an Fc domain carrying
the A2BG2 glycan in ALS blood induces neuron death by ADCC.
Accordingly, our results suggest an involvement of the activating
receptor FccRIII in the neuron loss, caused by an increase in the
affinity of ALS-IgG to FccRIIIA via the Fc glycan with its
bisecting GlcNAc lack of core fucose.
To summarize, in addition to the more sialylated and less
fucosylated glycans revealed in ALS patient sera, we have
demonstrated herein the involvement of a specific glycan structure
in neuroblastoma and NSC34 cell lysis. IgG previously found to
alter neuron functions, thereby determining neuron survival, were
shown here to potentially play a role in the cytolytic response
against neurons mediated by the Fc domain. We therefore,
propose an involvement of IgG Fc-glycan in neuron death in ALS,
which is governed by CD16 on microglia or infiltrating immune
cells. As well, we propose that glycans of IgG from ALS patients
may serve as a biomarker for the disease.
Supporting Information
Figure S1 Fractions of whole serum N-glycans. The total
N-glycans from individual samples of ALS patients or healthy
volunteers were fractionated by quantitative normal phase HPLC,
according to glucose units (GU). The thirteen observed fractions
were numbered, and each was pooled and subsequently digested
by exoglycosidase to determine glycan structures and amounts.
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Figure S2 Sequential exoglycosidase digestions of gly-
cans released from normal human serum IgG and
measured by NP-HPLC. The IgG glycan pool from individual
samples (undigested sample) was incubated sequentially with
Arthrobacter ureafaciens sialidase (ABS), bovine testes b-galacto-
sidase (BTG), Jack bean b-hexosaminidase (JBH) and Charonia
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separation of normal IgG glycans and the glycan structure
symbols.
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Figure S3 ALS-IgG co-localized with CD16 in spinal
cord tissues of 75-day old G93A-SOD1 mice. Representa-
tive confocal microscopic images of spinal cord slices taken from
75-day old G93A-SOD1 mice and age-matched littermates
stained for CD16, human IgG, and counterstained with nuclear
DAPI. Localization of ALS-IgG before and after PNGase-F
treatment and of healthy control-IgG in wild-type and mSOD1
spinal cord tissues (A) and co-localization of intact ALS-IgG with
NeuN (neurons) in mSOD1 spinal cord tissues (B).
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Table S1 Profiles of total N-Glycans derived from
pooled sera of ALS patients. Profiles were observed for both
pooled or individual sera of ALS patients and healthy control
candidates by using normal phase HPLC and MALDI-TOF MS
methods.
(DOC)
Table S2 Glycan structures.
(DOC)
Table S3 Profiles of N
297-Glycans derived from sera of
ALS patients. Profiles were observed for individual sera of ALS,
patients with inflammatory bowel disease, multiple sclerosis
patients, and healthy control candidates by using normal phase
HPLC and MALDI-TOF MS methods.
(DOC)
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